Navigation Links
ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Date:12/4/2007

proceed to Phase I clinical trials by the end of 2007. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the prospectus.

For further information please contact:

ThromboGenics

Prof. Desire Collen, CEO

Dr. Patrik De Haes, COO

Tel: +32(0)16-34-61-94

Citigate Dewe Rogerson

Valerie Auffray / David Dible / Amber Bielecka

Tel: +44(0)207-638-95-71

valerie.auffray@citigatedr.co.uk


'/>"/>
SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
6. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
7. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
9. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Arpida Presents Preclinical Data on AR-2474 at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... has been made aware of a fraudulent press release ... GlobeNewswire, purporting to be from Immunovaccine. This press release ... with Gilead Science, Inc. The press release did ... to the information contained within the press release. ...
(Date:2/27/2015)... Mass. , Feb. 27, 2015 ... of the NCATS rare-diseases portfolio " in ... a new financing technique to reduce the risk ... diseases and potentially unlock new levels of funding ... The product of a unique collaboration between scientists ...
(Date:2/27/2015)... 27, 2015 The fully automated ... UC) can sequentially analyze up to 48 samples ... high-sensitivity detection of targets by mass spectrometry. ... fulfill the measurement requirements of a wide range ... drug delivery and search for disease biomarkers, additives ...
(Date:2/27/2015)... FamilyFarms Group is pleased to announce its valued ... received the 2015 Tomorrow’s Top Producer Horizon Award. The ... 35, who has demonstrated excellence in the business of ... Tomorrow's Top Producer Horizon Award. Every year I look ... and learning from their experiences. It is truly humbling ...
Breaking Biology Technology:Immunovaccine Disclaims Hoax Press Release 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
... 25, 2011 Projects In Knowledge, a fully accredited ... digital and mobile information tools for busy clinicians, has ... The company,s website ( www.projectsinknowledge.com ) won an Award ... "Most Improved Web and Intranet Site." Launched in August ...
... Mich., July 25, 2011 Robert Ettinger, the founder of ... Saturday, July 23, at home in Clinton Township, Michigan, and ... storage at very low temperatures after death in the hope ... aging and disease. Mr. Ettinger wrote ...
... -   Text-to-speech application enables researchers to listen ...  Elsevier, a world leading provider of scientific, technical ... of an audio reader application from iSpeech, provider of cloud-based ... . The iSpeech Audio Reader is the latest in a ...
Cached Biology Technology:Two Health Industry Award Wins for Projects In Knowledge® 2Two Health Industry Award Wins for Projects In Knowledge® 3Founder of Cryonics Movement Dies, is Frozen at Cryonics Institute 2iSpeech® Develops Audio Reader for Elsevier's SciVerse Applications 2iSpeech® Develops Audio Reader for Elsevier's SciVerse Applications 3iSpeech® Develops Audio Reader for Elsevier's SciVerse Applications 4
(Date:2/5/2015)... Calif. , Jan. 30, 2015  It is ... great power and potential for genomic science as a ... in disease prevention and treatment.  I was honored to ... new, government-funded precision medicine program. Since ... the science of genomics—from the first sequenced genome of ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ( ... - A Global Market Overview" report to their offering. ... is to ensure that an individual is who she/he is ... make use of a person,s unique physical characteristics, such as ...
(Date:1/22/2015)... /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry news, ... website design. "When we launched FindBiometrics 12 years ... O,Neill , founder and CEO of FindBiometrics. "Now it,s maturing ... the key players on a very broad scale.  We are ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... in melanoma therapy. Patients whose melanoma lesions contain a ... a BRAF-specific inhibitor, PLX4032. Reports of the drug trial ... after therapy began the tumors returned and resumed growing. ... tumor learns to signal around the blocked gene by ...
... the southwestern United States are changing and will face ... declines during this century, according to a study conducted ... Service; University of California, Santa Barbara; U.S. Geological Survey; ... in the Proceedings of the National Academy of ...
... that the speed of early forest clearance following human ... much faster and more intense than previously thought. ... just a few large fires within 200 years of ... forest. Grasslands and shrubland replaced the burnt forest and ...
Cached Biology News:Killing drug-resistant melanoma requires combination therapy 2Killing drug-resistant melanoma requires combination therapy 3Drought and rising temperatures weaken southwest forests 2Early settlers rapidly transformed New Zealand forests with fire 2Early settlers rapidly transformed New Zealand forests with fire 3
Histone H2A Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Detects ~14 kDa Histone H2A. It does not cross-react with other Histones. Reacts with human/mouse/rat. Performs w...
...
CMRL Medium-1066 (1X) liquid...
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: